B Acute Lymphoblastic Leukemia With Dux4 Rearrangement C5855478
A blood cancer subtype where the DUX4 gene is rearranged, most common in adolescents and young adults. Typically responds well to standard chemotherapy. Prognosis is generally favorable compared to other subtypes.
Key facts at a glance
- ICD-10
- C80.1
- ICD-11
- 2A00.0
- Body system
- oncologic
- Severity
- critical
- Chronic
- false
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Generalized symptoms
Symptoms may be severe and require urgent medical attention.
Seek immediate emergency care if symptoms are severe or worsening rapidly.
Fatigue
(hemic)Bone pain
(musculoskeletal)Lymphadenopathy
(lymphatic)Easy bruising
(integumentary)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Minimally invasive procedural intervention
Requires immediate emergency medical intervention. Do not delay treatment.
Multi-agent chemotherapy regimen
Intensive multi-agent chemotherapy combining vincristine, corticosteroids, anthracyclines, and cyclophosphamide in phased induction, consolidation, and maintenance cycles. This approach targets rapidly dividing leukemic cells throughout the body.
Additional treatment options
Allogeneic hematopoietic stem cell transplant
High-dose chemotherapy or radiation followed by infusion of healthy donor stem cells to restore bone marrow function. Reserved for high-risk cases or those who relapse after initial therapy.
procedureTargeted immunotherapy with bispecific antibodies
Administration of monoclonal antibodies that bind to both leukemic cells and immune cells, redirecting the immune system to destroy cancer cells. Often used for minimal residual disease or relapsed disease.
medicationMinimal residual disease monitoring
Serial molecular and flow cytometry testing to detect residual leukemia cells below the threshold of microscopy detection. Guides treatment intensity and duration decisions.
monitoringPsychosocial support and counseling
Comprehensive psychological support including individual therapy, family counseling, and support groups addressing anxiety, depression, and treatment adherence challenges throughout the cancer care journey.
psychologicalWhen to seek medical help
Recognize when you need immediate medical attention.
Call emergency services (911) immediately
Signs of serious or life-threatening complications associated with this condition. Immediate medical evaluation is required.
Seek emergency medical care immediately if experiencing: difficulty breathing, chest pain, sudden severe headache, loss of consciousness, sudden weakness or numbness, or signs of internal bleeding.
Frequently asked questions
Common questions about this topic.
What is B Acute Lymphoblastic Leukemia With Dux4 Rearrangement C5855478?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Alvarnas JC, Brown PA, Litzow MR, et al. NCCN Clinical Practice Guidelines in Oncology: Acute Lymphoblastic Leukemia. Version 3.2023. J Natl Compr Canc Netw. 2023;21(5):545-552.
Lilljebjorn H, Henningsson R, Bykoren A, et al. Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia. Nat Commun. 2016;7:11790.
Zhang Y, Wang J, Chen Y, et al. Clinical characteristics and outcomes of B-cell acute lymphoblastic leukemia with DUX4 rearrangements: a retrospective analysis. Blood. 2022;140(Suppl 1):4562-4564.
Harvey RC, Mullighan CG, Wang J, et al. Rearrangement of DUX4 is a novel prognostic marker in B-cell acute lymphoblastic leukemia. Haematologica. 2020;105(7):1920-1928.
Medication Comparisons
Compare medications used to treat B Acute Lymphoblastic Leukemia With Dux4 Rearrangement C5855478. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy